Selarsdi Dosage
Generic name: USTEKINUMAB-AEKN 90mg in 1mL
Dosage form: injection, solution
Drug class: Interleukin inhibitors
Medically reviewed by Drugs.com. Last updated on Feb 28, 2025.
2.1 Recommended Dosage in Plaque Psoriasis
Subcutaneous Adult Dosage Regimen
- For patients weighing 100 kg or less, the recommended dosage is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.
- For patients weighing more than 100 kg, the recommended dosage is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.
In subjects weighing more than 100 kg, 45 mg was also shown to be efficacious. However, 90 mg resulted in greater efficacy in these subjects.
Subcutaneous Pediatric Dosage Regimen
Administer SELARSDI subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter.
The recommended dose of SELARSDI for pediatric patients (6 to 17 years old) with plaque psoriasis based on body weight is shown below (Table 1).
Body Weight of Patient at the Time of Dosing |
Recommended Dose |
less than 60 kg |
0.75 mg/kg |
60 kg to 100 kg |
45 mg |
more than 100 kg | 90 mg |
For pediatric patients weighing less than 60 kg, the administration volume for the recommended dose (0.75 mg/kg) is shown in Table 2; withdraw the appropriate volume from the single-dose vial.
Body Weight (kg) at the time of dosing |
Dose (mg) |
Volume of injection (mL) |
15 |
11.3 |
0.12 |
16 |
12.0 |
0.13 |
17 |
12.8 |
0.14 |
18 |
13.5 |
0.15 |
19 |
14.3 |
0.16 |
20 |
15.0 |
0.17 |
21 |
15.8 |
0.17 |
22 |
16.5 |
0.18 |
23 |
17.3 |
0.19 |
24 |
18.0 |
0.20 |
25 |
18.8 |
0.21 |
26 |
19.5 |
0.22 |
27 |
20.3 |
0.22 |
28 |
21.0 |
0.23 |
29 |
21.8 |
0.24 |
30 |
22.5 |
0.25 |
31 |
23.3 |
0.26 |
32 |
24 |
0.27 |
33 |
24.8 |
0.27 |
34 |
25.5 |
0.28 |
35 |
26.3 |
0.29 |
36 |
27 |
0.3 |
37 |
27.8 |
0.31 |
38 |
28.5 |
0.32 |
39 |
29.3 |
0.32 |
40 |
30 |
0.33 |
41 |
30.8 |
0.34 |
42 |
31.5 |
0.35 |
43 |
32.3 |
0.36 |
44 |
33 |
0.37 |
45 |
33.8 |
0.37 |
46 |
34.5 |
0.38 |
47 |
35.3 |
0.39 |
48 |
36 |
0.4 |
49 |
36.8 |
0.41 |
50 |
37.5 |
0.42 |
51 |
38.3 |
0.42 |
52 |
39 |
0.43 |
53 |
39.8 |
0.44 |
54 |
40.5 |
0.45 |
55 |
41.3 |
0.46 |
56 |
42 |
0.46 |
57 |
42.8 |
0.47 |
58 |
43.5 |
0.48 |
59 |
44.3 |
0.49 |
* Refer to 2.2 Psoriatic Arthritis; Subcutaneous Pediatric Dosage Regimen. |
2.2 Recommended Dosage in Psoriatic Arthritis
Subcutaneous Adult Dosage Regimen
- The recommended dosage is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.
- For patients with co-existent moderate-to-severe plaque psoriasis weighing more than 100 kg, the recommended dosage is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.
Subcutaneous Pediatric Dosage Regimen
Administer SELARSDI subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter.
The recommended dose of SELARSDI for pediatric patients (6 to 17 years old) with psoriatic arthritis, based on body weight, is shown below (Table 3).
Body Weight of Patient at the Time of Dosing |
Recommended Dose |
Less than 60 kg* |
0.75 mg/kg |
60 kg or more |
45 mg |
greater than 100 kg with co-existent moderate-to-severe plaque psoriasis |
90 mg |
* For pediatric patients weighing less than 60 kg, the administration volume for the recommended dose (0.75 mg/kg) is shown in Table 2; withdraw the appropriate volume from the single-dose vial. |
2.3 Recommended Dosage in Crohn’s Disease and Ulcerative Colitis
Intravenous Induction Adult Dosage Regimen
A single intravenous infusion dose of SELARSDI using the weight-based dosage regimen specified in Table 4
.
Body Weight of Patient at the time of dosing |
Dose |
Number of 130 mg/26 mL (5 mg/mL) SELARSDI vials |
55 kg or less |
260 mg |
2 |
more than 55 kg to 85 kg |
390 mg |
3 |
more than 85 kg |
520 mg |
4 |
Subcutaneous Maintenance Adult Dosage Regimen
The recommended maintenance dosage is a subcutaneous 90 mg dose administered 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.
2.4 General Considerations for Administration
- SELARSDI is intended for use under the guidance and supervision of a healthcare provider. SELARSDI should only be administered to patients who will be closely monitored and have regular follow-up visits with a healthcare provider. The appropriate dose should be determined by a healthcare provider using the patient’s current weight at the time of dosing. In pediatric patients, it is recommended that SELARSDI be administered by a healthcare provider. If a healthcare provider determines that it is appropriate, a patient may self-inject or a caregiver may inject SELARSDI after proper training in subcutaneous injection technique. Instruct patients to follow the directions provided in the Medication Guide.
- Not made with natural rubber latex.
- It is recommended that each injection be administered at a different anatomic location (such as upper arms, gluteal regions, thighs, or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, or indurated. When using the single-dose vial, a 1 mL syringe with a 27-gauge, 1/2 inch needle is recommended.
- Prior to administration, visually inspect SELARSDI for particulate matter and discoloration. SELARSDI is a clear and colorless to slightly yellow solution and free of visible particles. Do not use SELARSDI if it is discolored or cloudy, or if other particulate matter is present. SELARSDI does not contain preservatives; therefore, discard any unused product remaining in the vial and/or syringe.
Instructions for Administration of SELARSDI Prefilled Syringes Equipped with Passive Safety Device
Refer to the diagram below for the provided instructions.

Hold the SYRINGE BODY and remove the NEEDLE COVER. Do not hold the PLUNGER or PLUNGER HEAD while removing the NEEDLE COVER or the PLUNGER may move. Do not use the prefilled syringe if it is dropped without the NEEDLE COVER in place.
Inject SELARSDI subcutaneously as recommended.
Inject all of the medication by pushing in the PLUNGER HEAD all the way in until the plunger head is completely between the needle guard activation clips. Injection of the entire prefilled syringe contents is necessary to activate the passive safety device guard.

After injection, maintain the pressure on the PLUNGER HEAD and remove the needle from the skin. Slowly take your thumb off the PLUNGER HEAD. The PLUNGER will move up with your thumb and retract the needle into the needle guard, as shown by the illustration below:

Used syringes should be placed in a puncture-resistant container.
2.6 Preparation and Administration of SELARSDI 130 mg/26 mL (5 mg/mL) Vial for Intravenous Infusion (Crohn’s Disease and Ulcerative Colitis)
SELARSDI solution for intravenous infusion must be diluted, prepared and infused by a healthcare professional using aseptic technique.
- Calculate the dose and the number of SELARSDI vials needed based on patient weight (Table 4). Each 26 mL vial of SELARSDI contains 130 mg of ustekinumab-aekn.
- Withdraw, and then discard a volume of the 0.9% Sodium Chloride Injection from the 250 mL infusion bag equal to the volume of SELARSDI to be added (discard 26 mL sodium chloride for each vial of SELARSDI needed, for 2 vials- discard 52 mL, for 3 vials- discard 78 mL, 4 vials- discard 104 mL).
- Withdraw 26 mL of SELARSDI from each vial needed and add it to the 250 mL infusion bag. The final volume in the infusion bag should be 250 mL. Gently mix.
- Visually inspect the diluted solution before infusion. Do not use if visibly opaque particles, discoloration or foreign particles are observed.
- Infuse the diluted solution over a period of at least one hour. Once diluted, the infusion should be completely administered within four hours of the dilution in the infusion bag.
- Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 0.2 micrometer).
- Do not infuse SELARSDI concomitantly in the same intravenous line with other agents.
- SELARSDI does not contain preservatives. Each vial is for one-time use in only one patient. Discard any remaining solution. Dispose any unused medicinal product in accordance with local requirements.
Storage
If necessary, the diluted infusion solution may be kept at room temperature up to 25°C (77°F) for up to 4 hours. Protect the diluted solution from light. Storage time at room temperature begins once the diluted solution has been prepared. The infusion should be completed within 4 hours after the dilution in the infusion bag (cumulative time after preparation including the storage and the infusion period). Do not freeze. Discard any unused portion of the infusion solution.
Frequently asked questions
- What are biosimilar drugs and how do they compare to biologics?
- Do I qualify for the Stelara copay card, how much can I save?
- What are the new drugs for plaque psoriasis?
- What biosimilars have been approved in the United States?
- What is the mechanism of action of Stelara and how does it work?
- How quickly or how long before Stelara starts to work?
More about Selarsdi (ustekinumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
Patient resources
Other brands
Stelara, Steqeyma, Pyzchiva, Wezlana, ... +3 more
Professional resources
Other brands
Stelara, Steqeyma, Pyzchiva, Wezlana, ... +2 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.